Overview

A Phase III Study of Apixaban in Patients With Atrial Fibrillation

Status:
Completed
Trial end date:
2017-05-25
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to determine whether apixaban is more effective than acetylsalicylic acid in the prevention of strokes associated with patients with atrial fibrillation. The safety of this treatment will also be studied.
Phase:
Phase 3
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Pfizer
Treatments:
Apixaban
Aspirin